Monitoring adults after venous thromboembolism

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational cohort enrolls adults hospitalized in the Internal Medicine department at the University Hospital of Rouen who have a confirmed deep vein thrombosis or pulmonary embolism and whose case is presented to the hospital's thrombosis multidisciplinary meeting (RCP). Investigators will collect clinical data, apply validated risk scores such as HAS-BLED, VTE-BLED, and HERDOO2, and record management decisions including anticoagulant duration and bleeding or recurrent thrombotic events. The program includes dedicated post-emergency consultations to streamline outpatient follow-up and capture outcomes. The aim is to see whether combining standardized scores with routine multidisciplinary case review leads to safer, more individualized anticoagulant care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Any patient over 18 years of age who has experienced at least one venous thromboembolic episode:

   * Deep vein thrombosis confirmed by Doppler ultrasound or CT venography,
   * Pulmonary embolism confirmed by CT angiography, ventilation/perfusion scan, or confirmed DVT episode with respiratory signs consistent with PE.
2. Hospitalization in the Internal Medicine Department
3. Consultation by an Internal Medicine physician
4. File presented at the thrombosis multidisciplinary meeting

Exclusion Criteria:

Thrombosis not meeting the inclusion criteria (cerebral venous thrombosis, mesenteric)

Where it's running

• University Hospital of Rouen
  Rouen, France Recruiting

Study contacts

• Principal investigator: Sébastien SM MIRANDA, Doctor — University Hospital, Rouen
• Study coordinator: David DM MALLET, Director
• Email: David.Mallet@chu-rouen.fr
• Phone: 02 32 88 82 65

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Reduced‑dose apixaban or rivaroxaban versus daily low‑molecular‑weight heparin for people with blood cancers

  This trial will test whether reduced‑dose apixaban or rivaroxaban pills can prevent blood clots as well and as safely as daily low‑molecular‑weight heparin injections in people with hematologic malignancies.

  Recruiting Medical University of Gdansk · Gdansk, Pomeranian Voivodeship · NCT07270263

• Examining blood clotting in pregnant women and the effects of low molecular weight heparin

  This study looks at how blood clotting changes during and after pregnancy to see if a blood thinner called low molecular weight heparin works better for pregnant women at risk of blood clots.

  Recruiting University Hospital, Clermont-Ferrand · Clermont-Ferrand and 1 other locations · NCT06575309

• Comparing antithrombotic therapies for patients with acute venous thromboembolism and a history of cardiovascular disease

  This study is testing if combining blood thinners with another type of medication can help people with blood clots and a history of heart disease stay safe and healthy.

  Recruiting at 28 sites Phase 3 Centre Hospitalier Universitaire de Saint Etienne · Amiens and 27 other locations · NCT05627375

• Prolonged anticoagulation for preventing blood clots in autoimmune hemolytic anemia

  This study is testing if longer use of blood thinners can help prevent blood clots in people with autoimmune hemolytic anemia.

  Recruiting Phase 2 Centre Hospitalier Universitaire Dijon · Dijon · NCT05089227

• CHIPs-VTE program to prevent hospital-acquired blood clots in hospitalized patients

  This project tests whether a hospital-wide package of risk checks, computer alerts, staff education, and audits can increase appropriate clot-prevention for hospitalized patients in China.

  Recruiting China-Japan Friendship Hospital · Beijing, Beijing Municipality · NCT04211181

• Investigating risk factors for blood clots in women using hormonal treatments

  This study is trying to find out if family history affects the risk of blood clots in young women who use hormonal treatments like birth control or are pregnant.

  Recruiting at 8 sites University Hospital, Brest · Brest and 7 other locations · NCT03206372

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.